Our Industry Leading Partners
Almac Diagnostic Services
Almac Diagnostic Services is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories based in the UK and US, offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.
Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver on the promise of a healthier world.
Q² Solutions is a leading global clinical trials laboratory services organization that partners with biopharmaceutical, medical device and diagnostics customers to transform science and data into actionable medical insights. Its laboratory services span the development lifecycle from Discovery through Clinical Trials to Commercialization that includes predictive biomarker solutions for Companion Diagnostics.
Unilabs is a leader in Companion Diagnostic testing in Europe with several years of experience with the associated necessary global, customized logistics & regulatory know-how. Unilabs is Serving Pharma as a highly customer centric and specialized bioanalytical laboratory service partner with structured processes to reduce budget risks & stalling of drug development. Unilabs has more than 8.000 employees, and more than 30 years of clinical trials experience, handling more than 3.000 studies involving a broad range of matrices from numerous species and in a vast number of therapeutic areas.
Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.
From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.